Theratechnologies Inc T.TH

Question about Docetaxel & Th1902

[Hamilton02]

I was wondering the following :  Correct me if I missed something...

Docetaxel is often used at 75mg /m once every 3 weeks (month?)

The annual sales of Docetaxel in 2023 is around USD 115 billion and is projected to be USD 252 billion in 2032.

Theratechnologies have shown that there are no notable DLTs with the last cohort and not much before that as well for many patients. This, with about 3 times the dose (300mg/m).

Let's consider that they will succeed to show that their process with TH1902 each week for a total of 300mg/m has less or equal negative effect than Docetaxel alone at 75mg/m.

Wouldn't it be interesting for companies selling Docetaxel to add the peptide (well...using TH1902) to their treatments?

It seems that efficacy for ovarian cancer is less important than security with these patients that have shown very high resistance to many treatments before. Which is not the case when we use Docetaxel alone... or with other solutions to manage the negative effects.

Using 300mg/m on less resistant patients with less or same negative effect should show more efficacy, no?

[Mannequin]

Hi Hamilton,  Well, we don't know what we don't know. It comes down to the fact that we (and drug companies) need to see the results.  Then, if there is a benefit, can these buys and girls raise some cash from them to start trials?  This company has been incapable of doing anything positive for a decade. And, it's blown up for long term shareholders for that entire time

[scarlet1967]

      The communication has been poor and misleading. The executions or better said lack of them even worse. Personally when I listen to their conference calls remembering what was said during many previous calls which never materialized I find it hard to believe in many things they say. Without going in details in my opinion that's the reason for lack of

[Lee430]

Scarlet1967, Would you please enlighten us on what happens to participants in this PH1C trial as it moves along, If the drug is working for them do they continue the cycles and then are rolled into PH2 if all goes well?

[scarlet1967]

Hi Lee, It was originally scheduled to have a part 4 handpicking patient who has best responded to the drug. The company clearly has said after part 3 they will be looking for a partner in order to fund the trial. The perfect scenario would be if the patients who have been participating in the dose optimization with apparently so far no DLTs and some possibly efficacy results to move either on to